Literature DB >> 33476723

Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Alia Ghoneum1, Sameh Almousa1, Bailey Warren1, Ammar Yasser Abdulfattah2, Junjun Shu3, Hebatullah Abouelfadl4, Daniela Gonzalez1, Christopher Livingston1, Neveen Said5.   

Abstract

Platinum resistance in epithelial ovarian cancer (OvCa) is rising at an alarming rate, with recurrence of chemo-resistant high grade serous OvCa (HGSC) in roughly 75 % of all patients. Additionally, HGSC has an abysmal five-year survival rate, standing at 39 % and 17 % for FIGO stages III and IV, respectively. Herein we review the crucial cellular interactions between HGSC cells and the cellular and non-cellular components of the unique peritoneal tumor microenvironment (TME). We highlight the role of the extracellular matrix (ECM), ascitic fluid as well as the mesothelial cells, tumor associated macrophages, neutrophils, adipocytes and fibroblasts in platinum-resistance. Moreover, we underscore the importance of other immune-cell players in conferring resistance, including natural killer cells, myeloid-derived suppressive cells (MDSCs) and T-regulatory cells. We show the clinical relevance of the key platinum-resistant markers and their correlation with the major pathways perturbed in OvCa. In parallel, we discuss the effect of immunotherapies in re-sensitizing platinum-resistant patients to platinum-based drugs. Through detailed analysis of platinum-resistance in HGSC, we hope to advance the development of more effective therapy options for this aggressive disease.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ascitic fluid; Cisplatin-resistance; OvCa; TME

Mesh:

Substances:

Year:  2021        PMID: 33476723      PMCID: PMC8286277          DOI: 10.1016/j.semcancer.2020.12.024

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  242 in total

1.  Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

2.  Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.

Authors:  Xia Yuan; Jing Zhang; Dan Li; Ye Mao; Fei Mo; Wei Du; Xuelei Ma
Journal:  Gynecol Oncol       Date:  2017-07-08       Impact factor: 5.482

3.  A distinct innate lymphoid cell population regulates tumor-associated T cells.

Authors:  Sarah Q Crome; Linh T Nguyen; Sandra Lopez-Verges; S Y Cindy Yang; Bernard Martin; Jennifer Y Yam; Dylan J Johnson; Jessica Nie; Michael Pniak; Pei Hua Yen; Anca Milea; Ramlogan Sowamber; Sarah Rachel Katz; Marcus Q Bernardini; Blaise A Clarke; Patricia A Shaw; Philipp A Lang; Hal K Berman; Trevor J Pugh; Lewis L Lanier; Pamela S Ohashi
Journal:  Nat Med       Date:  2017-02-06       Impact factor: 53.440

Review 4.  Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Authors:  Roshan Agarwal; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

5.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.

Authors:  Anm Nazmul H Khan; Nonna Kolomeyevskaya; Kelly L Singel; Melissa J Grimm; Kirsten B Moysich; Sayeema Daudi; Kassondra S Grzankowski; Sashikant Lele; Lourdes Ylagan; Gill A Webster; Scott I Abrams; Kunle Odunsi; Brahm H Segal
Journal:  Oncotarget       Date:  2015-05-10

7.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Authors:  Thaïs Baert; Ann Vankerckhoven; Matteo Riva; Anaïs Van Hoylandt; Gitte Thirion; Gerhardt Holger; Thomas Mathivet; Ignace Vergote; An Coosemans
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

8.  Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway.

Authors:  Yu Wang; Jun Ma; Haoran Shen; Chengjie Wang; Yueping Sun; Stephen B Howell; Xinjian Lin
Journal:  Oncol Rep       Date:  2014-08-28       Impact factor: 3.906

Review 9.  Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.

Authors:  Yu-Hsuan Lai; Chin Kuo; Macus Tien Kuo; Helen H W Chen
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

Review 10.  Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.

Authors:  Fulvio Borella; Eleonora Ghisoni; Gaia Giannone; Stefano Cosma; Chiara Benedetto; Giorgio Valabrega; Dionyssios Katsaros
Journal:  Diagnostics (Basel)       Date:  2020-03-07
View more
  9 in total

Review 1.  Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.

Authors:  Mohammad Aslam Khan; Kunwar Somesh Vikramdeo; Sarabjeet Kour Sudan; Seema Singh; Annelise Wilhite; Santanu Dasgupta; Rodney Paul Rocconi; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2021-08-18       Impact factor: 15.707

2.  Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Authors:  Yi-Jou Tai; Cheng-Miao Ou; Ying-Cheng Chiang; Chi-Fang Chang; Chi-An Chen; Wen-Fang Cheng
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

3.  Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer.

Authors:  Rui Gou; Mingjun Zheng; Yuexin Hu; Lingling Gao; Shuang Wang; Ouxuan Liu; Xiao Li; Liancheng Zhu; Juanjuan Liu; Bei Lin
Journal:  BMC Cancer       Date:  2022-06-23       Impact factor: 4.638

4.  FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways.

Authors:  Xueyun Huo; Wenjing Zhang; Guannan Zhao; Zhenwen Chen; Peixin Dong; Hidemichi Watari; Ramesh Narayanan; Todd D Tillmanns; Lawrence M Pfeffer; Junming Yue
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

5.  The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.

Authors:  Zhen Tang; Hui Dong; Tian Li; Ning Wang; Xinghui Wei; Hao Wu; Yichao Liu; Wei Wang; Zheng Guo; Xin Xiao
Journal:  Oxid Med Cell Longev       Date:  2021-12-21       Impact factor: 6.543

6.  Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.

Authors:  Tingwei Liu; Jiacheng Shen; Qizhi He; Shaohua Xu
Journal:  Front Genet       Date:  2022-02-14       Impact factor: 4.599

7.  Immune Subtypes Characterization Identifies Clinical Prognosis, Tumor Microenvironment Infiltration, and Immune Response in Ovarian Cancer.

Authors:  Weihong Lu; Fei Zhang; Xiaolin Zhong; Jinhua Wei; Hongyang Xiao; Ruiqin Tu
Journal:  Front Mol Biosci       Date:  2022-03-21

Review 8.  Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components.

Authors:  Kaname Uno; Shohei Iyoshi; Masato Yoshihara; Kazuhisa Kitami; Kazumasa Mogi; Hiroki Fujimoto; Mai Sugiyama; Yoshihiro Koya; Yoshihiko Yamakita; Akihiro Nawa; Tomohiro Kanayama; Hiroyuki Tomita; Atsushi Enomoto; Hiroaki Kajiyama
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

Review 9.  Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report.

Authors:  Clelia Madeddu; Elisabetta Sanna; Sonia Nemolato; Olga Mulas; Sara Oppi; Mario Scartozzi; Giorgio La Nasa; Antonio Maccio
Journal:  Diagnostics (Basel)       Date:  2022-08-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.